Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AerovectRx Corp.
Mass-immunization device discussed at meeting
November 4th, 2005
AerovectRx Corp., developers of a pain-free nebulizer technology for mass-immunization and point-of care drug delivery, presented recently at Medtech Insight's "Investment In Innovation (In3) BOSTON: A Preview of Early-Stage Medical Technology Companies" conference in Boston, Massachusetts. "AerovectRx's unique, painless technology platform provides access to multiple drug delivery segments including the $17 billion respiratory care market as well as the multi-billion dollar vaccine delivery market, which includes influenza, measles, rubella, chicken pox, and tetanus just to name a few," said Matthew H.J. Kim, founder and CEO of AerovectRx. "We...
Source: Biotech Law Weekly (2005-11-04)
|
